Alimera Sciences Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Alimera Sciences stock.
View analyst ratings for Alimera Sciences or view top-rated stocks.

2 brokerages have issued twelve-month target prices for Alimera Sciences' shares. Their ALIM stock forecasts range from $8.00 to $11.00. On average, they anticipate Alimera Sciences' share price to reach $9.50 in the next year. This suggests a possible upside of 81.0% from the stock's current price.
View analysts' price targets for Alimera Sciences or view top-rated stocks among Wall Street analysts.

Alimera Sciences' stock was trading at $5.13 on January 1st, 2022. Since then, ALIM shares have increased by 2.3% and is now trading at $5.25.
View the best growth stocks for 2022 here.

Alimera Sciences is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Alimera Sciences.

Alimera Sciences, Inc. (NASDAQ:ALIM) posted its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.18. The biopharmaceutical company had revenue of $11.90 million for the quarter, compared to analysts' expectations of $13 million. During the same quarter in the previous year, the firm earned ($0.63) EPS.
View Alimera Sciences' earnings history.

Alimera Sciences's stock reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

2 employees have rated Alimera Sciences CEO Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among Alimera Sciences' employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Alimera Sciences include Nuvectis Pharma (NVCT), Pieris Pharmaceuticals (PIRS), TFF Pharmaceuticals (TFFP), Citius Pharmaceuticals (CTXR), Applied Molecular Transport (AMTI), Longeveron (LGVN), IO Biotech (IOBT), F-star Therapeutics (FSTX), Akouos (AKUS), Avadel Pharmaceuticals (AVDL), CorMedix (CRMD), CorMedix (CRMD), Ovid Therapeutics (OVID), LumiraDx (LMDX) and Nanobiotix (NBTX).
View all of ALIM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Alimera Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Healthcare of Ontario Pension Plan Trust Fund (3.58%), Renaissance Technologies LLC (1.78%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Alimera Sciences stock include James R Largent, John Philip Jones, John Snisarenko, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends for Alimera Sciences.

ALIM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold Alimera Sciences company stock in the last two years include Philip Ashman, and Stanley Morgan.
View insider buying and selling activity for Alimera Sciences or view top insider-selling stocks.

ALIM stock was acquired by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Alimera Sciences stock in the last two years include James R Largent, John Philip Jones, and Richard S Eiswirth Jr.
View insider buying and selling activity for Alimera Sciences or or view top insider-buying stocks.

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALIM stock can currently be purchased for approximately $5.25.

Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $36.77 million and generates $59.03 million in revenue each year. The biopharmaceutical company earns $-4.37 million in net income (profit) each year or ($1.01) on an earnings per share basis.

Alimera Sciences employs 145 workers across the globe.

Alimera Sciences was founded in 2003.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for Alimera Sciences is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at [email protected], or via fax at 678-990-5744.